Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps and rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 12, 2007, Pages 969-973

  Fong, Seng Lim ^a   Htay, Htay Han ^b   Bock, Hans L ^c  

^a NATIONAL HEALTHCARE GROUP POLYCLINICS   (Singapore)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GLAXOSMITHKLINE   (Singapore)

Author keywords

MMR; Priorix

Indexed keywords

ANTIBODY; LIVE VACCINE; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MUMPS ANTIBODY; RUBELLA ANTIBODY; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE CONVULSION; FEVER; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MEASLES; MEASLES VACCINATION; MUMPS; MUMPS VIRUS; NORMAL HUMAN; PAROTID GLAND DISEASE; PHASE 4 CLINICAL TRIAL; RASH; RHINITIS; RUBELLA; SALIVARY GLAND DISEASE; SAMPLE SIZE; SEROCONVERSION; SIDE EFFECT; SINGAPORE; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS STRAIN;

EID: 39749131697     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. World Health Organization. Expanded programme on immunisation. Progress towards measles elimination. Available at: www.wpro.who.int/NR/rdonlyres/ 9BCEF3D2-7D04-46FC-AE99-1CA6F8B59DE5/0/01_EPI.pdf. Accessed 16 October 2006.
2. World Health Organization. Measles: Mortality Reduction and Regional Elimination. Strategic plan 2001-2005. Available at: http://www.who.int/ vaccines-documents/. Accessed 16 October 2006.
3. World Health Organization. Measles vaccines. Wkly Epidemiol Rec 2004;79:130-42.
4. World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec 2001;76:346-55.
5. Usonis V, Bakasenas V, Bock H, Chitour K, Clemens R. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Infection 1998;26:222-6.
6. Gatchalian S, Cordero-Yap L, Lu-Fong M, Soriano R, Ludan A, Chitour K, et al. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Southeast Asian J Trop Med Public Health 1999;30:511-7.
7. Ipp M, Cohen E, Goldbach M, Macarthur C. Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants. Arch Pediatr Adolescent Med 2004;158:323-6.
8. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organisation 1999;77:3-14.
9. Centers for Disease Control and Prevention (CDC). Progress in reducing measles mortality-worldwide, 1999-2003. MMWR Morb Mortal Wkly Rep 2005;54:200-3.
10. Goh KT. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet 1999;354:1355-6.
11. Brown EG, Wright KE. Genetic studies on a mumps vaccine strain associated with meningitis. Rev Med Virol 1998;8:129-42.
12. MCA U. Medicines Control Agency, annual report and accounts 2002/03. 2003. Available at: http://www.mhra.gov.uk/. Accessed 16 October 2006.
13. Furesz J, Contreras G. Vaccine-related mumps meningitis-Canada. Can Dis Wkly Rep 1990;16:253-4.
14. Lim CS, Chan KP, Goh KT, Chow VT. Hemagglutinin-neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore. J Med Virol 2003;70:287-92.
15. Committee on Epidemic Diseases. Efficacy of mumps virus vaccine. Epidemiol News Bull 2000;26:45-7.
16. Pons C, Pelayo T, Pachon I, Galmes A, Gonzalez L, Sanchez C, et al. Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy. Euro Surveill 2000;5:80-4.
17. Goncalves G, De Araujo A, Monteiro Cardoso ML. Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveill 1998;3:119-21.
18. Schlegel M, Osterwalder JJ, Galeazzi RL, Vernazza PL. Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ 1999;319:352. Erratum in: BMJ 1999;319:477
19. Germann D, Strohle A, Eggenberger K, Steiner CA, Matter I. An outbreak of mumps in a population partially vaccinated with the Rubini strain. Scand J Infect Dis 1996;28:235-8.
20. Wellington K, Goa KL. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs 2003;63:2107-26.
21. Crovari P, Gabutti G, Giammanco G, Dentico P, Moiraghi AR, Ponzio F, et al; The Cooperative Group for the study of MMR vaccines. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. Vaccine 2000;18:2796-803.
22. Stuck B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol 2002;20:113-20.
23. Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999;18:42-8.
24. Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994;331:1397-402.
25. Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Mortimer EA editors. Vaccines. Philadelphia: Saunders, 1994:277-301.
26. Cochi SL, Wharton M, Plotkin SA. Mumps vaccine. In: Plotkin SA, Mortimer EA editors. Vaccines. Philadelphia: Saunders, 1994:277-301.
27. Plotkin S. Rubella vaccine. In: Plotkin SA, Mortimer EA, edition. Vaccines. Philadelphia: Saunders, 1994:303-26.
28. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, et al. Measles antibody reevaluation of protective titres. J Infect Dis 1990;162:1036-42.
29. Samb B, Aaby P, Whittle HL, Seek AM, Rahman S, Bennett J, et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995;14:203-9.
30. Skendzel LP. Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 1996;106:170-4.
31. Hilleman MR, Weibel RE, Buynak EB, Stokes J Jr, Whitman JE. Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. N Engl J Med 1967;276:252-8.
32. Weibel RE, Buynak EB, Mc Lean AA, Roehm RR, Hilleman MR. Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med 1980;165:260-3.
33. Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect 2005;51:294-8.